Skip to main content
. 2023 Mar 17;16(3):455. doi: 10.3390/ph16030455

Table 1.

Total ADRs reported in EV related to DOACs.

Drug Total ADRs % of Total
Dabigatran 57,627 13.49%
Rivaroxaban 131,182 30.70%
Apixaban 70,424 16.48%
Edoxaban 9318 2.18%
Other ACs 158,767 37.15%
427,318